The binding site of human adenosine deaminase for CD26/dipeptidyl peptidase IV: The Arg142Gln mutation impairs binding to CD26 but does not cause immune deficiency

Journal of Experimental Medicine

Volumn 192, Issue 9, 2000, Pages 1223-1235

  Richard, Eva ^a   Arredondo Vega, Francisco X ^a   Santisteban, Ines ^a   Kelly, Susan J ^a   Patel, Dhavalkumar D ^a   Hershfield, Michael S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenosine deaminase complexing protein; Adenosine deaminase deficiency; Protein protein interaction; Severe combined immunodeficiency; T lymphocyte

Indexed keywords

ADENOSINE DEAMINASE; ARGININE; DIPEPTIDYL PEPTIDASE IV; GLUTAMINE;

ARTICLE; BINDING SITE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME DEFICIENCY; ERYTHROCYTE; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADENOSINE DEAMINASE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, CD26; BINDING SITES; CATTLE; CELLS, CULTURED; FLOW CYTOMETRY; GENE DELETION; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; POINT MUTATION; PROTEIN BINDING; RABBITS; RECOMBINANT FUSION PROTEINS; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTES;

EID: 0034613689     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.192.9.1223     Document Type: Article

References (68)

1. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity
2. Immunodeficiency caused by deficiency of adenosine deaminase
3. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. 7th ed
4. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice
5. Adenosine deaminase-deficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death
6. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency
7. Multiple forms of human adenosine deaminase. II. Isolation and properties of a conversion factor from human lung
8. Human adenosine deaminase binding protein. Assay, purification, and properties
9. The adenosine deaminase binding protein of human skin fibroblasts is located on the cell surface
10. Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction
11. Distribution of adenosine deaminase complexing protein (ADCP) in human tissues
12. Studies on the effects of infusion of enzyme inhibitors on mouse adenosine deaminase
13. Distribution of adenosine deaminase-complexing protein in murine tissues
14. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase
15. Direct association of adenosine deaminase with a T cell activation antigen, CD26
16. TA1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody
17. The T cell triggering molecule Tp103 is associated with dipeptidyl peptidase IV activity
18. CD26 antigen is a surface dipeptidyl peptidase IV (DPPIV) as characterized by monoclonal antibodies clone TII-19-4-7 and 4EL1C7
19. Dipeptidyl peptidase IV (CD26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation
20. Cloning and functional expression of the T cell activation antigen CD26
21. CD26: A surface protease involved in T-cell activation
22. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation
23. Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted B propeller domain
24. The structure and function of CD26 in the T-cell immune response
25. Evidence that thymocyte activating molecule is mouse CD26 (dipeptidyl peptidase IV)
26. Thymocyte costimulating antigen is CD26 (dipeptidyl peptidase IV). Costimulation of granulocyte, macrophage, and T cell lineage cell proliferation via CD26
27. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes
28. Paradoxical expression of adenosine deaminase in T cells cultured from a patient with adenosine deaminase deficiency and combined immunodeficiency
29. New chromogenic substrates for X-prolyl dipeptidyl-aminopeptidase
30. Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26/dipeptidyl peptidase IV (EC 3.4.14.5)
31. Adenosine deaminase complexing proteins of the rabbit
32. Sequence of human adenosine deaminase cDNA including the coding region and a small intron
33. Identification of functional murine adenosine deaminase cDNA clones by complementation in Escherichia coli
34. Site-directed mutagenesis by overlap extension using the polymerase chain reaction
35. Adenosine deaminase deficiency in adults
36. Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: Implications for evolution of a CpG hotspot and expression of a transduced ADA cDNA
37. Hot spot mutations in adenosine deaminase deficiency
38. Novel deletion and a new missense mutation (Glu 217 Lys) at the catalytic site in two adenosine deaminase alleles of a patient with neonatal onset adenosine deaminase - Severe combined immunodeficiency
39. Adenosine deaminase deficiency: Genotype-phenotype correlations based on expressed activity of 29 mutant alleles
40. Deduced amino acid sequence of Escherichia coli adenosine deaminase reveals evolutionarily conserved amino acid residues: Implications for catalytic function
41. Atomic structure of adenosine deaminase complexed with a transition-state analog: Understanding catalysis and immunodeficiency mutations
42. Novel splicing, missense, and deletion mutations in 7 adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease. Contribution of genotype to phenotype
43. Immunoreactive protein in adenosine deaminase deficient human lymphoblast cell lines
44. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response
45. Automated enzymatic measurement of adenosine deaminase isoenzyme activities in serum
46. Three-dimensional structures of the free and antigen-bound Fab from monoclonal antilysozyme antibody HyHEL-63
47. Adult onset immunodeficiency caused by inherited adenosine deaminase deficiency
48. Deficiency of adenosine deaminase not associated with severe combined immunodeficiency
49. Overview of biochemical abnormalities and molecular genetics of adenosine deaminase deficiency
50. Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: A model for immunodeficiency disease
51. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes
52. Adenosine, deoxyadenosine, and deoxyguanosine induce DNA cleavage in mouse thymocytes
53. p53 Expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency
54. Bcl-2 relieves deoxyadenylate stress and suppresses apoptosis in pre-B leukemia cells
55. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c
56. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
57. Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex
58. Adenosine deaminase deficiency: Molecular basis and recent developments
59. Nucleoside and nucleobase transport systems of mammalian cells
60. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency
61. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase
62. An active-site mutation (Gly633→Arg) of dipeptidyl peptidase IV causes its retention and rapid degradation in the endoplasmic reticulum
63. Biosynthesis and degradation of altered immature forms of intestinal dipeptidyl peptidase IV in a rat strain lacking the enzyme
64. Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains
65. Genetic evidence for the role of DPPIV in intestinal hydrolysis and assimilation of prolyl peptides